SG10201912846PA - Therapeutic agent for non-motor symptoms associated with parkinson's disease - Google Patents
Therapeutic agent for non-motor symptoms associated with parkinson's diseaseInfo
- Publication number
- SG10201912846PA SG10201912846PA SG10201912846PA SG10201912846PA SG10201912846PA SG 10201912846P A SG10201912846P A SG 10201912846PA SG 10201912846P A SG10201912846P A SG 10201912846PA SG 10201912846P A SG10201912846P A SG 10201912846PA SG 10201912846P A SG10201912846P A SG 10201912846PA
- Authority
- SG
- Singapore
- Prior art keywords
- parkinson
- disease
- therapeutic agent
- symptoms associated
- motor symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017004498 | 2017-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912846PA true SG10201912846PA (en) | 2020-02-27 |
Family
ID=62840494
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912846PA SG10201912846PA (en) | 2017-01-13 | 2018-01-12 | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
| SG11201906289YA SG11201906289YA (en) | 2017-01-13 | 2018-01-12 | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906289YA SG11201906289YA (en) | 2017-01-13 | 2018-01-12 | Therapeutic agent for non-motor symptoms associated with parkinson's disease |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11576897B2 (en) |
| EP (1) | EP3569233A4 (en) |
| JP (1) | JP7219091B2 (en) |
| KR (1) | KR20190105015A (en) |
| CN (1) | CN110430875A (en) |
| AU (1) | AU2018208321A1 (en) |
| CA (1) | CA3049319A1 (en) |
| PH (1) | PH12019501615A1 (en) |
| SG (2) | SG10201912846PA (en) |
| TW (1) | TWI761425B (en) |
| WO (1) | WO2018131672A1 (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| US20060003996A1 (en) * | 2002-06-17 | 2006-01-05 | Stephen Roth | Intralesional treatment of psoriasis |
| ES2264003T3 (en) * | 2002-10-07 | 2006-12-16 | Glaxo Group Limited | DERIVATIVES OF SULFONAMIDE AS ANTIPSYTIC AGENTS. |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| TWI415845B (en) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| US8569353B2 (en) * | 2010-07-15 | 2013-10-29 | Dainippon Sumitomo Pharma Co., Ltd. | Pyrazole compound |
| JP2015129094A (en) * | 2012-04-16 | 2015-07-16 | 大日本住友製薬株式会社 | Arylaminopyrazole derivative |
-
2018
- 2018-01-12 SG SG10201912846PA patent/SG10201912846PA/en unknown
- 2018-01-12 TW TW107101269A patent/TWI761425B/en not_active IP Right Cessation
- 2018-01-12 SG SG11201906289YA patent/SG11201906289YA/en unknown
- 2018-01-12 AU AU2018208321A patent/AU2018208321A1/en not_active Withdrawn
- 2018-01-12 CA CA3049319A patent/CA3049319A1/en active Pending
- 2018-01-12 KR KR1020197021411A patent/KR20190105015A/en active Search and Examination
- 2018-01-12 EP EP18739127.1A patent/EP3569233A4/en not_active Withdrawn
- 2018-01-12 WO PCT/JP2018/000568 patent/WO2018131672A1/en unknown
- 2018-01-12 US US16/476,925 patent/US11576897B2/en active Active
- 2018-01-12 CN CN201880018126.8A patent/CN110430875A/en active Pending
- 2018-01-12 JP JP2018561424A patent/JP7219091B2/en active Active
-
2019
- 2019-07-10 PH PH12019501615A patent/PH12019501615A1/en unknown
-
2022
- 2022-12-28 US US18/089,752 patent/US20230149357A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3049319A1 (en) | 2018-07-19 |
| AU2018208321A1 (en) | 2019-07-18 |
| JP7219091B2 (en) | 2023-02-07 |
| US20230149357A1 (en) | 2023-05-18 |
| WO2018131672A1 (en) | 2018-07-19 |
| US20210299099A1 (en) | 2021-09-30 |
| KR20190105015A (en) | 2019-09-11 |
| EP3569233A4 (en) | 2020-09-30 |
| EP3569233A1 (en) | 2019-11-20 |
| TWI761425B (en) | 2022-04-21 |
| SG11201906289YA (en) | 2019-08-27 |
| PH12019501615A1 (en) | 2019-11-04 |
| TW201831452A (en) | 2018-09-01 |
| CN110430875A (en) | 2019-11-08 |
| US11576897B2 (en) | 2023-02-14 |
| JPWO2018131672A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280530A (en) | Aadc polynucleotides for the treatment of parkinson's disease | |
| SG11201912154XA (en) | Aadc polynucleotides for the treatment of parkinson's disease | |
| IL274648A (en) | New catecholamine prodrugs for use in the treatment of parkinson's disease | |
| PL2968218T3 (en) | Combination for the treatment of parkinson's disease | |
| IL263188B (en) | Treatment for parkinson's disease | |
| PT3302454T (en) | Compositions for use in treating parkinson's disease and related disorders | |
| ZA201804079B (en) | Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease | |
| ZA202004433B (en) | Therapeutic agent for nervous system disease | |
| EP3555319C0 (en) | Diagnosis of parkinson's disease on the basis of decreased overall translation | |
| GB201522416D0 (en) | Wilson's disease gene therapy | |
| EP3538095A4 (en) | Methods for treating parkinson's disease | |
| EP2968222A4 (en) | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease | |
| SG10201912846PA (en) | Therapeutic agent for non-motor symptoms associated with parkinson's disease | |
| IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease | |
| GB201610205D0 (en) | Therapies for parkinson's disease | |
| GB201518052D0 (en) | Parkinson's disease treatment | |
| HK1244449A1 (en) | Methods for treating psychosis associated with parkinson's disease | |
| PL3352777T3 (en) | Engrailed for use in the treatment of dna-damage in a patient suffering from parkinson disease | |
| GB201504144D0 (en) | Treatment of Parkinson's disease | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| IL241397A0 (en) | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |